ArmaGen Technologies, Inc.:製薬企業の治療薬開発パイプライン2014

◆英語タイトル:ArmaGen Technologies, Inc. - Product Pipeline Review - 2014
◆商品コード:GMDHC06257CDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年10月25日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

ArmaGen Technologies, Inc. – Product Pipeline Review – 2014

Summary

Global Markets Direct’s, ‘ArmaGen Technologies, Inc. – Product Pipeline Review – 2014’, provides an overview of the ArmaGen Technologies, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ArmaGen Technologies, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ArmaGen Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ArmaGen Technologies, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ArmaGen Technologies, Inc.’s pipeline products

Reasons to buy

- Evaluate ArmaGen Technologies, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ArmaGen Technologies, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ArmaGen Technologies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ArmaGen Technologies, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ArmaGen Technologies, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ArmaGen Technologies, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ArmaGen Technologies, Inc. Snapshot 5
ArmaGen Technologies, Inc. Overview 5
Key Information 5
Key Facts 5
ArmaGen Technologies, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
ArmaGen Technologies, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
ArmaGen Technologies, Inc. – Pipeline Products Glance 10
ArmaGen Technologies, Inc. – Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
ArmaGen Technologies, Inc. – Drug Profiles 12
AGT-110 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
AGT-115 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
AGT-160 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AGT-181 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
AGT-182 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AGT-183 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
AGT-190 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
AGT-184 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ArmaGen Technologies, Inc. – Pipeline Analysis 21
ArmaGen Technologies, Inc. – Pipeline Products by Target 21
ArmaGen Technologies, Inc. – Pipeline Products by Route of Administration 22
ArmaGen Technologies, Inc. – Pipeline Products by Molecule Type 23
ArmaGen Technologies, Inc. – Pipeline Products by Mechanism of Action 24
ArmaGen Technologies, Inc. – Recent Pipeline Updates 25
ArmaGen Technologies, Inc. – Dormant Projects 27
ArmaGen Technologies, Inc. – Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables
ArmaGen Technologies, Inc., Key Information 5
ArmaGen Technologies, Inc., Key Facts 5
ArmaGen Technologies, Inc. - Pipeline by Indication, 2014 7
ArmaGen Technologies, Inc. - Pipeline by Stage of Development, 2014 8
ArmaGen Technologies, Inc. - Monotherapy Products in Pipeline, 2014 9
ArmaGen Technologies, Inc. - Preclinical, 2014 10
ArmaGen Technologies, Inc. - Discovery, 2014 11
ArmaGen Technologies, Inc. - Pipeline by Target, 2014 21
ArmaGen Technologies, Inc. - Pipeline by Route of Administration, 2014 22
ArmaGen Technologies, Inc. - Pipeline by Molecule Type, 2014 23
ArmaGen Technologies, Inc. - Pipeline Products by Mechanism of Action, 2014 24
ArmaGen Technologies, Inc. - Recent Pipeline Updates, 2014 25
ArmaGen Technologies, Inc. - Dormant Developmental Projects,2014 27

List of Figures
ArmaGen Technologies, Inc. - Pipeline by Top 10 Indication, 2014 7
ArmaGen Technologies, Inc. - Pipeline by Stage of Development, 2014 8
ArmaGen Technologies, Inc. - Monotherapy Products in Pipeline, 2014 9
ArmaGen Technologies, Inc. - Pipeline by Top 10 Target, 2014 21
ArmaGen Technologies, Inc. - Pipeline by Top 10 Molecule Type, 2014 23
ArmaGen Technologies, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 24

【レポートのキーワード】

製薬、研究開発、治験、製品パイプライン、医薬品、概要

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ArmaGen Technologies, Inc.:製薬企業の治療薬開発パイプライン2014]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆